First Trust Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-533,507
| Closed | -$7.6M | – | 2653 |
|
|
2025
Q4 | $7.6M | Buy |
533,507
+376,840
| +241% | +$3.7M | 0.01% | 1213 |
|
|
2025
Q3 | $1.23M | Buy |
156,667
+22,128
| +16% | +$157K | ﹤0.01% | 2034 |
|
|
2025
Q2 | $771K | Buy |
134,539
+4,537
| +3% | +$29.3K | ﹤0.01% | 2147 |
|
|
2025
Q1 | $1.06M | Sell |
130,002
-29,812
| -19% | -$276K | ﹤0.01% | 2033 |
|
|
2024
Q4 | $1.51M | Buy |
159,814
+989
| +0.6% | +$10.3K | ﹤0.01% | 1911 |
|
|
2024
Q3 | $1.7M | Buy |
158,825
+125,470
| +376% | +$1.37M | ﹤0.01% | 1832 |
|
|
2024
Q2 | $331K | Sell |
33,355
-286,313
| -90% | -$2.94M | ﹤0.01% | 2192 |
|
|
2024
Q1 | $3.77M | Buy |
319,668
+203,422
| +175% | +$2.6M | ﹤0.01% | 1442 |
|
|
2023
Q4 | $1.65M | Sell |
116,246
-206,440
| -64% | -$2.34M | ﹤0.01% | 1799 |
|
|
2023
Q3 | $3.92M | Buy |
322,686
+312,508
| +3,070% | +$4.03M | ﹤0.01% | 1354 |
|
|
2023
Q2 | $128K | Sell |
10,178
-196,091
| -95% | -$2.33M | ﹤0.01% | 2322 |
|
|
2023
Q1 | $2.29M | Sell |
206,269
-9,779
| -5% | -$121K | ﹤0.01% | 1630 |
|
|
2022
Q4 | $2.64M | Sell |
216,048
-69,935
| -24% | -$787K | ﹤0.01% | 1569 |
|
|
2022
Q3 | $2.99M | Buy |
285,983
+151,631
| +113% | +$1.69M | ﹤0.01% | 1457 |
|
|
2022
Q2 | $1.44M | Buy |
134,352
+10,660
| +9% | +$87.8K | ﹤0.01% | 1839 |
|
|
2022
Q1 | $1.17M | Sell |
123,692
-44,736
| -27% | -$419K | ﹤0.01% | 1993 |
|
|
2021
Q4 | $1.95M | Buy |
+168,428
| New | +$1.88M | ﹤0.01% | 1802 |
|
|
2021
Q2 | – | Sell |
-288,291
| Closed | -$2.85M | – | 2505 |
|
|
2021
Q1 | $2.85M | Buy |
288,291
+18,927
| +7% | +$293K | ﹤0.01% | 1575 |
|
|
2020
Q4 | $6.22M | Buy |
269,364
+101,814
| +61% | +$2.08M | 0.01% | 1007 |
|
|
2020
Q3 | $2.37M | Sell |
167,550
-2,488
| -1% | -$36.3K | ﹤0.01% | 1288 |
|
|
2020
Q2 | $2.56M | Buy |
170,038
+43,890
| +35% | +$535K | ﹤0.01% | 1260 |
|
|
2020
Q1 | $1.17M | Buy |
126,148
+110,838
| +724% | +$1.05M | ﹤0.01% | 1549 |
|
|
2019
Q4 | $149K | Sell |
15,310
-85,388
| -85% | -$782K | ﹤0.01% | 2343 |
|
|
2019
Q3 | $808K | Sell |
100,698
-143,852
| -59% | -$1.56M | ﹤0.01% | 1948 |
|
|
2019
Q2 | $3.05M | Buy |
244,550
+197,880
| +424% | +$2.51M | 0.01% | 1330 |
|
|
2019
Q1 | $635K | Buy |
+46,670
| New | +$570K | ﹤0.01% | 2046 |
|
|
2018
Q4 | – | Sell |
-213,396
| Closed | -$2.58M | – | 2428 |
|
|
2018
Q3 | $2.58M | Buy |
213,396
+29,046
| +16% | +$406K | ﹤0.01% | 1519 |
|
|
2018
Q2 | $2.88M | Buy |
184,350
+21,483
| +13% | +$325K | 0.01% | 1408 |
|
|
2018
Q1 | $2.45M | Buy |
+162,867
| New | +$2.48M | 0.01% | 1343 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
First Trust Advisors's FOLD Position: Q1 2026 in Review
First Trust Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 533,507 shares — an estimated $7.6M sold.
First Trust Advisors first reported a position in FOLD in Q1 2018 and held it in 29 quarters. The position peaked at $7.6M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- First Trust Advisors reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
- First Trust Advisors sold 533,507 Amicus Therapeutics shares in Q1 2026, an estimated $7.6M.
- First Trust Advisors first reported a position in Amicus Therapeutics in Q1 2018 and held it in 29 quarters.
- First Trust Advisors's Amicus Therapeutics position peaked at $7.6M in Q4 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.